A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (<scp>CBCRT</scp>01)Jianghao Chen, Ling Wang, Juliang Zhang et al.|International Journal of Cancer|2017Cited by 30
Vitamin C Treatment Rescues Prelamin A-Induced Premature Senescence of Subchondral Bone Mesenchymal Stem CellsYannv Qu, Xiaohua Xie, Li Zhang et al.|Stem Cells International|2020Cited by 15